Hysong Micah R, Shuey Megan M, Huffman Jennifer E, Auer Paul, Reiner Alexander, Raffield Laura M
Department of Genetics, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
Vanderbilt Genetics Institute and Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Blood Adv. 2025 Mar 25;9(6):1452-1462. doi: 10.1182/bloodadvances.2024014399.
A wealth of research focused on African American populations has connected rs2814778-CC ("Duffy-null") to decreased neutrophil (neutropenia) and leukocyte counts (leukopenia). Although it has been proposed that this variant is benign, prior studies have shown that the misinterpretation of Duffy-null-associated neutropenia and leukopenia can lead to unnecessary bone marrow biopsies, inequities in cytotoxic and chemotherapeutic treatment courses, underenrollment in clinical trials, and other disparities. To investigate the phenotypic correlates of Duffy-null status, we conducted a phenome-wide association study across >1400 clinical conditions in All of Us, the Vanderbilt University Medical Center's Biobank, and the Million Veteran Program. This reveals that Duffy-null status is only reproducibly associated with changes in white blood cell count and not with any disease outcomes. Moreover, we find that Duffy-null-associated neutropenia is on average less severe than other neutropenia cases in All of Us. We also show that this genotype is present in considerable frequencies in All of Us populations that are genetically similar to African (68%) and Middle Eastern (14%) 1000 Genomes/Human Genome Diversity Project reference populations as well as those who identify with >1 race (12%), as Pacific Islander (7%), and as Hispanic (5%). Furthermore, we find that race is not an accurate predictor of Duffy-null status or associated benign neutropenia. Our research suggests that broad genetic screening of rs2814778 across all populations could provide a more robust and accurate understanding of white blood cell count and mitigate resulting health disparities.
大量针对非裔美国人的研究将rs2814778-CC(“达菲阴性”)与中性粒细胞减少(嗜中性白血球减少症)和白细胞计数降低(白细胞减少症)联系起来。尽管有人提出这种变异是良性的,但先前的研究表明,对达菲阴性相关的嗜中性白血球减少症和白细胞减少症的错误解读可能导致不必要的骨髓活检、细胞毒性和化疗疗程的不平等、临床试验入组不足以及其他差异。为了研究达菲阴性状态的表型相关性,我们在范德堡大学医学中心生物样本库“我们所有人”项目以及百万退伍军人计划中,针对1400多种临床病症进行了全表型关联研究。这表明达菲阴性状态仅可重复地与白细胞计数变化相关,而与任何疾病结局无关。此外,我们发现在“我们所有人”项目中,达菲阴性相关的嗜中性白血球减少症平均比其他嗜中性白血球减少症病例的病情要轻。我们还表明,在“我们所有人”项目的人群中,这种基因型的出现频率相当高,这些人群在基因上与非洲(68%)和中东(14%)1000基因组/人类基因组多样性项目参考人群相似,以及那些认同多种族(12%)、太平洋岛民(7%)和西班牙裔(5%)的人群。此外,我们发现种族并不是达菲阴性状态或相关良性嗜中性白血球减少症的准确预测指标。我们的研究表明,对所有人群进行rs2814778的广泛基因筛查,可以更全面、准确地了解白细胞计数,并减少由此产生的健康差异。